---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-008569"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-01-16T23:59:59+00:00"
generated_at: "2026-06-06T23:21:23.734285+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Mirum Pharmaceuticals promotes Peter Radovich to President effective Jan 16, 2024

## Summary
- Peter Radovich promoted to President, effective Jan 16, 2024, while continuing as COO.
- Christopher Peetz remains CEO; Radovich had served as COO since April 2020.
- Radovich previously held senior roles at Global Blood Therapeutics and Onyx Pharmaceuticals.
- Promotion expands Radovich's responsibilities but no change in CEO role.

## SEC filing metadata
- accession: 0001193125-24-008569
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-01-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312524008569/0001193125-24-008569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312524008569/d723597d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-008569
- JSON: https://secwatch.observer/filing/0001193125-24-008569.json
- Plain text: https://secwatch.observer/filing/0001193125-24-008569.txt

## Key facts
- Executive change
  Peter Radovich changed role as President at Mirum Pharmaceuticals, Inc..
  - Action: promoted
  - Role: President
  source text: On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312524008569/0001193125-24-008569-index.htm
- Executive change
  Christopher Peetz changed role as Chief Executive Officer at Mirum Pharmaceuticals, Inc..
  - Role: Chief Executive Officer
  source text: On January 11, 2024, the Board of Directors of Mirum Pharmaceuticals, Inc. (the “Company”) promoted Peter Radovich, previously the Company’s Chief Operating Officer, to the additional position of President, with Christopher Peetz, who previously served as the Company’s President and Chief Executive Officer, continuing to serve as the Company’s Chief Executive Officer, each effective as of January 16, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312524008569/0001193125-24-008569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.